Trials / Unknown
UnknownNCT04928625
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1904 in Patients With Advanced Pancreatic Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1904 | SHR-A1904 |
Timeline
- Start date
- 2021-08-06
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
- First posted
- 2021-06-16
- Last updated
- 2021-08-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04928625. Inclusion in this directory is not an endorsement.